Compare GOCO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | XLO |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 39.4M |
| IPO Year | 2020 | 2021 |
| Metric | GOCO | XLO |
|---|---|---|
| Price | $1.57 | $0.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.00 | $2.00 |
| AVG Volume (30 Days) | 34.1K | ★ 478.3K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.82 | 60.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $798,894,000.00 | $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.74 | N/A |
| 52 Week Low | $1.31 | $0.50 |
| 52 Week High | $16.40 | $1.18 |
| Indicator | GOCO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 37.47 |
| Support Level | N/A | $0.50 |
| Resistance Level | $2.56 | $0.74 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 37.14 | 26.85 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.